Cisplatin concurrent with definitive RT (larynx-preservation CRT; RTOG 91-11)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Components	`DRUG-CISPLATIN`

ID	`REG-CISPLATIN-CONCURRENT-RT-LARYNX`
Type	Regimen
Status	reviewed 2026-07-11 \| pending_clinical_signoff
Diseases	None declared
Sources	`SRC-NCCN-HNSCC-2025` `SRC-RTOG-9111-FORASTIERE-2003`

Notes

STUB pending Clinical Co-Lead sign-off (CHARTER §6.1). Models the concurrent-cisplatin backbone of RTOG 91-11 (Forastiere NEJM 2003): cisplatin 100 mg/m² IV days 1, 22, 43 concurrent with 70 Gy / 35 fx definitive RT (see RC-LARYNGEAL-LA-CRT-RTOG9111). Carboplatin substitution for cisplatin-ineligible patients is NOT formally RTOG-91-11-validated — flagged explicitly in dose_adjustments rather than presented as trial-proven.

Used By

Indication

IND-LARYNGEAL-LA-1L-CRT - IND-LARYNGEAL-LA-1L-CRT

Radiation Courses

RC-LARYNGEAL-LA-CRT-RTOG9111 - Definitive concurrent chemoradiation for larynx preservation (RTOG 91-11)